CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.

Naert T, Tulkens D, Van Nieuwenhuysen T, Przybyl J, Demuynck S, van de Rijn M, Al-Jazrawe M, Alman BA, Coucke PJ, De Leeneer K, Vanhove C, Savvides SN, Creytens D, Vleminckx K.

Open source

DOI
10.1073/pnas.2115116118
Published
2021-11-01
Container
Proc Natl Acad Sci U S A
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1073/pnas.2115116118,
  title = {CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.},
  author = {Naert T and  Tulkens D and  Van Nieuwenhuysen T and  Przybyl J and  Demuynck S and  van de Rijn M and  Al-Jazrawe M and  Alman BA and  Coucke PJ and  De Leeneer K and  Vanhove C and  Savvides SN and  Creytens D and  Vleminckx K.},
  year = {2021},
  journal = {Proc Natl Acad Sci U S A},
  doi = {10.1073/pnas.2115116118},
  url = {https://doi.org/10.1073/pnas.2115116118}
}

RIS

TY  - JOUR
TI  - CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
AU  - Naert T
AU  -  Tulkens D
AU  -  Van Nieuwenhuysen T
AU  -  Przybyl J
AU  -  Demuynck S
AU  -  van de Rijn M
AU  -  Al-Jazrawe M
AU  -  Alman BA
AU  -  Coucke PJ
AU  -  De Leeneer K
AU  -  Vanhove C
AU  -  Savvides SN
AU  -  Creytens D
AU  -  Vleminckx K.
PY  - 2021
JO  - Proc Natl Acad Sci U S A
DO  - 10.1073/pnas.2115116118
UR  - https://doi.org/10.1073/pnas.2115116118
ER  - 

APA

T, N., D, T., T, V. N., J, P., S, D., M, V. D. R., M, A., BA, A., PJ, C., K, D. L., C, V., SN, S., D, C., & K., V. (2021). CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.2115116118

Source records